NTLA
NASDAQIntellia Therapeutics Inc.
News · 26 weeks60+17%
2026-03-012026-08-23
Mix2590d
- Insider11(44%)
- Other6(24%)
- SEC Filings5(20%)
- Analyst1(4%)
- Earnings1(4%)
- Offering1(4%)
Latest news
25 items- INSIDERPresident and CEO Leonard John M sold $286,819 worth of shares (22,675 units at $12.65) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,147,064 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- SECSEC Form 144 filed by Intellia Therapeutics Inc.144 - Intellia Therapeutics, Inc. (0001652130) (Subject)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 38,200 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of
- SECSEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)
- SECSEC Form 10-Q filed by Intellia Therapeutics Inc.10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesPositive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patientsEnded second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least into 2028 CAMBRIDGE, Mass., Aug. 06, 2026 (G
- PRIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesCAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates. To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conferen
- INSIDEREVP, Chief Financial Officer Dulac Edward J Iii sold $91,249 worth of shares (8,111 units at $11.25), decreasing direct ownership by 5% to 148,175 units (SEC Form 4) to satisfy withholding tax4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- ANALYSTIntellia Therapeutics downgraded by Wolfe Research with a new price targetWolfe Research downgraded Intellia Therapeutics from Peer Perform to Underperform and set a new price target of $9.00
- INSIDERVP, Chief Accounting Officer Dube Michael P sold $44,316 worth of shares (2,641 units at $16.78), decreasing direct ownership by 4% to 66,886 units (SEC Form 4) (tax liability)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDEREVP, Chief Financial Officer Dulac Edward J Iii sold $84,186 worth of shares (4,677 units at $18.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 156,286 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee o
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaData from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Cl
- INSIDERDirector Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 47,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or
- PRIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States. Late-Brea
NTLA FAQ
7 questionsWhat does Intellia Therapeutics Inc. do?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...Where does NTLA stock trade?
Intellia Therapeutics Inc. (NTLA) is listed on NASDAQ.What sector and industry is NTLA in?
Intellia Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Intellia Therapeutics Inc. go public?
Intellia Therapeutics Inc. (NTLA) completed its IPO in 2016.What are analysts saying about NTLA?
Intellia Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Underperform with a $900.00 price target on 2026-07-16. Recent price targets range from $500.00 to $1400.00.What companies are similar to NTLA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare NTLA side-by-side with any of them on Quantisnow.How can I track NTLA on Quantisnow?
Quantisnow aggregates Intellia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NTLA to receive live email and push alerts on every new disclosure.